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ARTICLE
IL-15 and PIM kinases direct the metabolic
programming of intestinal intraepithelial
lymphocytes
Olivia J. James1, Maud Vandereyken1, Julia M. Marchingo 2, Francois Singh1, Susan E. Bray3, Jamie Wilson4,
Andrew G. Love1 & Mahima Swamy 1✉
Intestinal intraepithelial lymphocytes (IEL) are an abundant population of tissue-resident
T cells that protect and maintain the intestinal barrier. IEL respond to epithelial cell-derived
IL-15, which is complexed to the IL-15 receptor α chain (IL-15/Rα). IL-15 is essential both for
maintaining IEL homeostasis and inducing IEL responses to epithelial stress, which has been
associated with Coeliac disease. Here, we apply quantitative mass spectrometry to IL-15/Rα-
stimulated IEL to investigate how IL-15 directly regulates inflammatory functions of IEL. IL-15/
Rα drives IEL activation through cell cycle regulation, upregulation of metabolic machinery
and expression of a select repertoire of cell surface receptors. IL-15/Rα selectively upregu-
lates the Ser/Thr kinases PIM1 and PIM2, which are essential for IEL to proliferate, grow and
upregulate granzyme B in response to inflammatory IL-15. Notably, IEL from patients with
Coeliac disease have high PIM expression. Together, these data indicate PIM kinases as
important effectors of IEL responses to inflammatory IL-15.
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Intraepithelial lymphocytes (IEL) are a specialised lymphoidcompartment in the intestinal epithelium, comprising a het-erogeneous population of T lymphocytes1. IEL express either
the αβ T cell antigen receptor (TCR) or the γδ TCR, alongside
TCR co-receptors CD8αβ or CD8αα and to a lesser extent CD4
(+/−). The most prevalent IEL subsets within the epithelium of the
mouse small intestine are those expressing TCRγδ and CD8αα
(TCRγδCD8αα), which account for ~50% of the total IEL pool,
with the remaining mostly being TCRαβCD8αβ or TCRαβCD8αα-
expressing cells. In human guts, TCRαβCD8αβ and TCRαβCD4
make-up the majority of IEL, with TCRγδ IEL contributing
<5–20% of the IEL compartment2. IEL are constantly exposed to
commensal bacteria, dietary antigens, and potential pathogens at
the intestinal epithelium, and are tasked with responding to epi-
thelial stress and protecting the intestinal barrier from external
insults. How IEL get activated is a matter of debate; but IEL do not
solely depend on TCR stimulation for their activation, rather,
signals from the microenvironment are important for commu-
nicating compromised barrier integrity to the surrounding IEL
and eliciting an effective immune response. One such signal is the
common γ-chain (γc) family cytokine IL-15.
IL-15 is produced by a wide range of cells including non-
hematopoietic cells such as intestinal epithelial cells (IEC) and its
expression is elevated in the gut microenvironment during tissue
stress or infection3. IL-15 is commonly presented to surrounding
IEL in a cell contact-dependent manner, known as trans-pre-
sentation, by IEC expressing IL-15 bound to the high-affinity IL-
15 receptor α subunit (IL-15Rα)4. IL-15/Rα interacts with the β
(CD122) and γc subunits present on the surface of IEL, initiating
JAK/STAT-mediated signalling events that alter lymphocyte
function5. It is well established that IEL require IL-15 for their
survival in the small intestine6, and development and maturation
of CD8αα IEL can be rescued in IL-15Rα−/− mice by restoring
IL-15Rα expression to the intestinal epithelium4.
IL-15 impacts more than just IEL survival. IL-15 induces
proliferation and cytolytic effector function in human IEL
in vitro7. Importantly, elevated intestinal IL-15 expression is
associated with increased numbers of cytotoxic IEL in the small
intestine of Coeliac disease (CeD) patients8, attributed to IL-15-
driven survival and proliferative expansion of IEL9,10. CeD is an
autoimmune enteropathy whereby genetically susceptible indivi-
duals have an adverse reaction to gluten, causing immune-
mediated damage to the small intestine. IEL derived from patients
with CeD have elevated expression of activating NK cell receptors
such as NKG2D and CD94 and expand massively in response to
elevated levels of IL-159,11. These findings suggest that regulation
of epithelial expression of IL-15 is a key mechanism by which IEL
activity is controlled. Thus, for IEL to utilise IL-15 as a survival
stimulus but also respond to rising levels of IL-15 as a ‘danger
signal’, IEL responses to IL-15 must be tightly controlled. How-
ever, the mechanism by which IL-15 mediates IEL function is
poorly understood.
Much of the data we have on effects of IL-15 on IEL have been
derived from CeD patients and from ‘healthy’ IEL obtained from
oesophagus-gastro-duodenoscopies for non-CeD complaints, or
from gastric bypasses for morbidly obese patients11–13. Due to the
cell contact-dependent mechanism of IL-15 presentation, it is
likely that IEL from CeD patients, and indeed, other entero-
pathies, receive additional stress signals from the IEC that they
are in contact with in vivo. For example, the stress-induced
NKG2D ligands, MIC-A and MIC-B, are elevated on damaged
IEC in CeD, and can activate IEL11,12,14. IEL are also exposed to
IL-21 and interferons in CeD15,16, and it is unclear how many of
these factors are present in so-called healthy human controls.
Hence, it is not currently clear how IL-15 directly affects IEL in
the absence of any other stress-related stimuli.
Here, we investigate the intrinsic effects of exposure to elevated
levels of IL-15 on IEL. We take a systematic unbiased approach
using high-resolution quantitative proteomics to define the global
changes induced in purified TCRγδCD8αα, TCRαβCD8αα and
TCRαβCD8αβ IEL subpopulations after 24 h exposure to IL-15.
Our data show how IL-15 regulates the activation status of IEL
through the upregulation of various activating and inhibitory
receptors, biosynthetic and bioenergetic activation, and induction
of proliferation. Importantly, these data reveal a critical role for
the proto-oncogenes PIM1 and PIM2 kinases in IL-15-induced
proliferation, growth, and acquisition of effector function in IEL.
Results
Proteome profiling reveals distinct features of IL-15/Rα sti-
mulated IEL. Here, we used quantitative label-free high-resolu-
tion mass spectrometry to explore how IL-15 shapes the
proteome of the main mouse IEL subsets: TCRαβCD8αβ,
TCRαβCD8αα and TCRγδCD8αα (Supplementary Fig. 1a).
Importantly, we used IL-15/Rα complexes to better mimic the
trans-presentation of IL-15 by IEC, and because it is more
representative of physiological conditions17,18. For IL-15-induced
activation, IEL were treated for 24 h with 100 ng/mL IL-15/Rα
(3.4 nM), based on pSTAT5 induction (Supplementary Fig. 1b)
and higher survival (Fig. 1a) observed at this concentration.
Untreated controls were derived directly ex vivo, as IEL do not
survive well in culture with low concentrations, or in complete
absence of IL-15 (Fig. 1a).
We identified and quantified >7500 proteins in the total dataset
(4 biological replicates/population; ±IL-15/Rα), providing high-
resolution quantitative proteomes of three developmentally
diverse IEL populations. Intensities were converted into estimated
protein copy number per cell using the proteomic histone ruler
method19,20. Both intensities and copy numbers showed good
correlation between replicates and subsets, despite their differ-
ences in ontogeny. All IEL subsets had similar protein content
(~40–50 pg/cell), and this was not significantly changed by IL-15
(Fig. 1b). These data indicate that different IEL subsets are similar
in their protein make-up and overall protein abundance
(Supplementary Fig. 1c, d).
To investigate how IL-15 differentially altered the proteomic
landscape of each subset, we calculated the fold change in
expression of proteins (IL-15-treated vs untreated) and found that
IL-15 largely drove the upregulation of proteins in all IEL subsets
(Fig. 1c and Supplementary Data 3). Interestingly, IL-15 had the
strongest impact on TCRαβCD8αβ IEL, with >600 proteins being
significantly upregulated >2-fold, approximately twice as many as
in TCRαβCD8αα and TCRγδCD8αα IEL. This was surprising, as
TCRαβCD8αβ IEL expressed the lowest copies of IL2Rβ (CD122),
the IL-15 receptor subunit necessary for signal transduction
downstream of IL-15 (Supplementary Fig. 1e). However, the
phosphorylation of STAT5 both ex vivo and in response to IL-15/
Rα stimulation was comparable in all three subsets (Supplemen-
tary Fig. 1f). These data suggest that CD122 levels on
TCRαβCD8αβ IEL are sufficient to activate downstream signal-
ling at a similar level to that seen in the other IEL subsets.
To identify shared IL-15 targets in IEL, we next asked which
proteins were commonly regulated by IL-15 among IEL subsets.
IL-15/Rα stimulation led to the downregulation of relatively few
proteins, with only 5 being significantly downregulated >2-fold in
all three IEL subsets (Fig. 1d, Supplementary Data 1). On the
other hand, we identified 95 proteins that were significantly
upregulated >2-fold in all IEL subsets, and >240 proteins
significantly upregulated in 2 or more subsets (Fig. 1e). Func-
tional annotation clustering revealed that the IL-15-upregulated
proteome was most enriched for proteins involved in processes
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Fig. 1 Global effects of IL-15/Rα stimulation on the proteomes of the three main IEL subsets. a Bar chart shows the percentage of live cells following
24 h IL-15/Rα (100 ng/mL) stimulation of CD8+ IEL (left, n= 6 biologically independent experiments) and Fluorescence activated cell sorting (FACS)-
purified IEL subsets (right, n= 4 biologically independent samples) (gating strategy shown in Supplementary Fig. 1a). Percentages were calculated from the
number of cells that were considered live (negative for DAPI staining) following IL-15/Rα treatment for 24 h, divided by the number of cells seeded for
culture (1 million/mL). b The protein content (pg/cell) of each IEL subset ± 24h IL-15/Rα stimulation. The number of proteins identified by average copy
number expression in each subset are displayed on the respective bars (n= 4 biologically independent samples). c Volcano plots show the differential
expression of proteins following IL-15 stimulation for each IEL subset. Data are presented as the distribution of the copy number ratio (IL-15-treated vs
untreated) (log2 (fold change)) against the inverse significance value (−log10(p-value)). Proteins were considered differentially expressed following IL-15
stimulation if the log2 fold-change value was >1 (>2-fold) in either an upregulated or downregulated direction. The grey area depicts the cut-off for proteins
deemed to have an insignificant fold change (p-value >0.05). Hence, proteins in colour were deemed significantly changed following IL-15 stimulation.
Statistical significance was derived from two-tailed empirical Bayes moderated t-statistics performed in limma on total proteome, see Supplementary
Data 3. d, e Venn diagrams show the commonality of proteins significantly downregulated and upregulated (>2-fold), respectively, between all IEL subsets
following 24 h IL-15/Rα stimulation. f Top 10 functional clusters enriched in proteins that were commonly 2-fold upregulated by IL-15/Rα stimulation in at
least 2 IEL subsets, as in e. See also supplementary Data 2. All error bars are mean ± s.e.m.
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such as DNA replication and repair; cell cycle; and ribosome
biogenesis (Fig. 1f and Supplementary Data 2). The analyses also
highlighted that the upregulated proteins were highly enriched for
transferases, including kinases, synthases and methyltransferases;
as well as cell surface receptors and adhesion molecules. In
summary, these data reveal many previously unrecognised
pathways in the IL-15-regulated proteome of IEL.
IL-15 drives IEL proliferation by triggering G1/S transition.
IEL maintained in 100 ng/mL IL-15/Rα increased in numbers
over 96 h (Fig. 2a), whereas low concentrations of the cytokine
complex (2 ng/mL) were only enough to maintain a proportion of
the starting IEL numbers. This indicated that higher concentra-
tions of IL-15/Rα either enhanced survival or proliferation, or
both, in IEL. We found that primary IEL expressed the pro-
survival proteins Bcl2, Bcl-XL and Mcl1, and both Bcl2 and Mcl1
were more highly expressed following IL-15/Rα stimulation
(Fig. 2b). To assess proliferation, we used CellTrace CFSE and
found that IEL started to divide at 48 h in response to 100 ng/mL
IL-15/Rα but did not divide at all in low levels, even after 4 days
(Fig. 2c). These data support the notion that strong IL-15 signals
are required for inducing IEL proliferation, as suggested by the
functional annotation clustering (Fig. 1f). We next investigated
the expression of cell cycle proteins and found that IL-15-treated
IEL had elevated expression of D-type cyclins and the associated
cyclin-dependent kinase CDK6 (Fig. 2d, e). To prevent transition
into the S phase of the cell cycle, the cyclin-dependent kinase
inhibitor 1B (CDKN1B or p27) binds to and inhibits downstream
cell cycle targets such as D-type cyclins and CDK6. Our data
revealed a downregulation of p27 by IL-15/Rα (Fig. 2e), sug-
gesting that IL-15 drives G1/S transition by downregulating cell
cycle inhibitors such as p27 and upregulating positive regulators
of the cell cycle. DNA synthesis measurements using EdU in IEL
cultured in IL-15/Rα confirmed that only 100 ng/mL triggered
entry of IEL into the S phase of the cell cycle after 48 h as
compared to 10 ng/mL (Fig. 2f). Overall, these data indicate that
strong IL-15/Rα signals trigger proliferation of IEL by regulating
key cell cycle checkpoint proteins to allow IEL exit from
quiescence.
IL-15 stimulation triggers biosynthetic pathways in IEL. A key
feature of T cell activation is a massive increase in cell size fuelled
by an increase in the uptake of nutrients and metabolic
reprogramming21. IEL already bear many hallmarks of activation,
including high granzyme, CD69 and CD44 expression, but are
still small, metabolically quiescent cells22. Although we did not
detect an increase in the overall protein content at the 24 h
timepoint used in the proteomic experiment (Fig. 1b), IEL
maintained in 100 ng/mL IL-15/Rα increased in size and granu-
larity by 48 h and continued to grow over 96 h, as compared to
those maintained in 2 ng/mL IL-15/Rα (Fig. 3a). Therefore, we
interrogated the proteomic data to gain insights into the bio-
synthetic and bioenergetic machinery and mechanisms by which
IL-15 might drive this expansion in cell size.
rRNA synthesis and ribosome biogenesis were highlighted as
significantly enriched pathways in the functional annotation
clustering (Fig. 1f) and further investigation revealed these
proteins largely related to the 90 S pre-ribosome, the earliest
stable assembly intermediate in the formation of eukaryotic
ribosomes (Fig. 3b). This data corresponded with an overall
increase in the total ribosome content (pg/cell) following IL-15
stimulation in all IEL subsets (Fig. 3c). Since increased ribosomal
biogenesis should enhance protein translation, we assessed the
effects of IL-15 stimulation on protein synthesis using O-
propargyl-puromycin (OPP) labelling. OPP is incorporated into
nascent polypeptide chains and when labelled with a fluorophore,
permits measurement of rates of translation. IEL cultured in 100
ng/mL IL-15/Rα for 48 h showed an increase in protein synthesis
after 15 min of OPP-labelling (Fig. 3d). In contrast, cells cultured
in 10 ng/mL IL-15/Rα did not show any labelling above
cycloheximide (CHX) treated controls. Thus, strong IL-15/Rα
signalling triggers increased protein synthesis in IEL by enhan-
cing ribosome biogenesis.
Given the increase in protein synthesis in IL-15-stimulated IEL,
we next assessed how IL-15 altered the expression of limiting
nutrient transporters that provide biosynthetic precursors for
anabolic processes. We observed a significant increase in the
expression of various nutrient transporters including the transferrin
receptor (TfR/CD71), zinc transporters ZIP6 and ZIP10, large
neutral amino acid transporter, SLC7A5/LAT1, and neutral amino
acid transporters, SLC38A2/SNAT2 and SLC1A5/ASCT2, upon IL-
15/Rα stimulation (Fig. 3e), many of which are key nutrient
transporters for T cell activation23–25. Using flow cytometry, we
confirmed elevated expression of CD71 and for CD98 (SLC3A2),
the heavy chain associated with SLC7A transporters, in response to
IL-15 stimulation (Fig. 3f). These data suggest that IL-15/Rα
enhances the ability of IEL to take up amino acids, the building
blocks for protein synthesis, and other nutrients essential for
optimal T cell function, such as iron and zinc26,27.
Conventional T cells increase their capacity for both glycolysis
and oxidative phosphorylation (OXPHOS) upon activation to
satisfy their increased bioenergetic and biosynthetic demands21.
IL-15 marginally increased the expression of glucose transporter
GLUT1 from <1000 copies to ~2000–3000 copies/cell (Fig. 4a). In
contrast to conventional activated CD8 T cells, which preferen-
tially express high levels of GLUT128, our proteomic data revealed
that IEL have abundant basal expression of the high-affinity
glucose transporter GLUT3 (~20,000 copies) (Fig. 4a), matching
that expressed on activated CD8 T cells (~25,000 molecules/
cell)28. We measured glucose levels in the media of IEL cultured
with IL-15/Rα and found a decrease specifically in cultures with
100 ng/mL of IL-15/Rα (Fig. 4b). Of the known players in glucose
metabolising pathways, we found that IL-15 induced the
upregulation of the glucose phosphorylating enzyme hexokinase
2 (HK2)29 and the lactate exporters MCT1 and MCT3 (Fig. 4c).
To investigate whether IEL metabolised glucose through
glycolysis, we measured lactate output in IEL cultured in IL-15/
Rα and found that 100 ng/mL IL-15/Rα specifically increased
production of lactate over 72 h (Fig. 4d). These data indicate that
the small, but significant changes in GLUT1, HK2 and lactate
transporter expression translate to increased glycolysis in IL-15/
Rα-stimulated IEL.
As glucose also contributes to OXPHOS in activated T cells30,
we next assessed mitochondrial respiratory capacity of IL-15-
stimulated IEL using high-resolution oxygraphy. The data show
that strong IL-15/Rα signals trigger an increase in basal oxygen
consumption at the cellular level (Fig. 4e, BASAL). Further
analyses were performed in permeabilised cells to permit addition
of exogenous mitochondrial complex substrates, inhibitors, and
ADP. This approach allowed us to evaluate the contributions of
individual mitochondrial complexes to the increased mitochon-
drial respiration. Based on these analyses, we could attribute the
increase in mitochondrial respiration to an increase in maximal
OXPHOS respiration through Complexes I+ II (GMSP), and to
increased electron transfer system capacity (ETC), suggesting an
enhanced transfer of electrons from complex II to complexes III
and IV. These data indicate that IL-15 stimulation increased
mitochondrial function and spare respiratory capacity, which
resulted in an overall increase in OXPHOS. Taken together, IL-15
triggered multiple biosynthetic pathways to enable the switch
from resting to active IEL.
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Cytotoxic effector function of IL-15/Rα-stimulated IEL. Thus
far we have focussed on the enriched pathways in the IL-15/Rα
regulated IEL proteome. However, a key question in IEL biology
is how IL-15 triggers cytotoxicity of IEL towards surrounding IEC
to contribute to the pathology of CeD. The enhancement of IEL
cytotoxicity by IL-15 has been attributed to an increase in GzmB
expression in IEL, and to changes in NK receptor expression. Our
proteomic data revealed that all IEL subsets expressed very high
levels of GzmA and GzmB in the resting state (5–20 million and
2–4 million copies/cell, respectively) and levels of perforin that
were comparable to effector T cells (ref. 31 and Fig. 5a). IL-15 led
to a modest upregulation of GzmB expression, which we con-
firmed by flow cytometry (Fig. 5b). Interestingly, we observed no
difference in GzmA copies but detected a decrease in GzmA by
flow cytometry in IEL cultured for 24 h in IL-15/Rα (Fig. 5a, b).
We further investigated the expression of several key proteins
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Fig. 2 IL-15/Rα stimulation drives proliferation of IEL by licensing the G1/S transition. a Total numbers of live CD8+ IEL following culture with IL-15/Rα
(100 ng/mL or 2 ng/mL) (0–72 h n= 7, 96 h n= 6 biologically independent experiments). b Estimated copy numbers/cell of survival proteins Bcl2, Bcl2l1
(Bcl-xL) and Mcl1 in each IEL subset ± 24 h 100 ng/mL IL-15/Rα stimulation (n= 4 biologically independent samples). c IEL were stained with CellTrace
CFSE prior to stimulation with either 2 ng/mL (grey) or 100 ng/mL (blue) IL-15/Rα for 4 days. Every 24 h cells were stained for subsets; TCRαβCD8αβ,
TCRαβCD8αα, TCRγδCD8αα and CFSE expression was analysed by flow cytometry (gating strategy as in Supplementary Fig. 1a). The discrete peaks in the
histograms represent successive generations of live, DAPI-negative IEL (representative of n= 3 biologically independent experiments). d Estimated copy
numbers/cell of cyclin-dependent kinase 6(CDK6) ± 24h 100 ng/mL IL-15/Rα stimulation (n= 4 biologically independent samples), exact p-values are
provided in Supplementary Data 3. e Heatmap for proteins involved in G1 to S phase transition of the cell cycle. Heatmap squares are corresponding log2
fold-change in copy number expression (IL-15-treated vs unstimulated) for each IEL subset. Asterisks depict significantly changed proteins (p < 0.05)
identified in the pathway analysis, exact p-values can be found in Supplementary Data 2. f IEL were stimulated with either 10 ng/mL or 100 ng/mL IL-15/Rα
for 48 h. Cells were stained for IEL subsets (gating strategy shown in Supplementary Fig. 6a) and DNA synthesis was assessed by incorporation of Ethynyl-
deoxyuridine (EdU) (representative of n= 2 biologically independent samples). All error bars are mean ± s.e.m. For all proteomic data (b, d, e), statistical
significance was derived from two-tailed empirical Bayes moderated t-statistics performed in limma on total proteome, see Supplementary Data 3.
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involved in degranulation, including the Munc family of proteins,
STXBP2, and Munc13-4 (Unc13d), the Rab GTPase RAB27A and
perforin. None of these proteins were regulated by IL-15 (Fig. 5a),
confirming the idea that IEL are already fully primed for acti-
vation and degranulation.
Given these data, we asked whether IL-15 enhanced cytotoxic
activity in IEL, and whether this was dependent on granzymes. Ex
vivo IEL only efficiently killed K562 target cells in a redirected
killing assay in the presence of 100 ng/mL IL-15/Rα (Fig. 5c).
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Fig. 3 IL-15/Rα increases IEL protein synthesis, nutrient uptake and growth. a Dot plots (representative of n= 3 independent experiments) show the
forward scatter (FSC, indicator of cell size) vs side scatter (SSC, indicator of granularity) of live IEL over 96 h culture in either 2 ng/mL or 100 ng/mL IL-15/
Rα. b Heatmap for proteins pertaining to the pre-90S ribosome. Heatmap squares are corresponding log2 fold-change in copy number expression (IL-15-
treated vs unstimulated) for each IEL subset. Asterisks depict significantly changed proteins (p < 0.05) identified in the pathway analysis, exact p-values
can be found in Supplementary Data 2. c Bar graph shows the protein content (pg/cell) of the sum of ribosomal proteins (GO:0005840) identified in all
IEL subsets ± 24 h IL-15/Rα stimulation (n= 4 biologically independent samples). Statistical significance was derived from two-way ANOVA with Sidak’s
multiple comparisons test. d OPP incorporation in IEL (n= 3 biologically independent experiments) cultured with 10 ng/mL or 100 ng/mL IL-15/Rα for 48
h. As a negative control, incorporation was inhibited by cycloheximide (CHX) pre-treatment in IEL cultured with 100 ng/mL IL-15/Rα. Histograms show
OPP incorporation in CHX-treated IEL (grey filled), IEL treated with 10 ng/mL IL-15/Rα (black) and IEL treated with 100 ng/mL IL-15/Rα (blue). Bar graph
shows the geometric mean fluorescence intensity (GEO MFI) of OPP in each IEL subset (gating strategy shown in Supplementary Fig. 6b), statistical
significance was derived from two-way ANOVA with Sidak’s multiple comparisons test. e Dot plot shows the log2 fold-change of nutrient transporters
significantly (p < 0.05) differentially expressed in the proteomic dataset. f Flow cytometric analyses of CD98 and CD71 expression from IEL cultured for
72 h in either 2 ng/mL or 100 ng/mL IL-15/Rα (gating strategy as in Supplementary Fig. 1a). Data is presented as mean fluorescence intensity (MFI) (n= 3
biologically independent experiments), statistical significance was derived from two-way ANOVA with Sidak’s multiple comparisons test. All error bars are
mean ± s.e.m. For all proteomic data (b, e), statistical significance was derived from two-tailed empirical Bayes moderated t-statistics performed in limma
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Fig. 4 IL-15/Rα stimulation increases mitochondrial respiration in IEL. a Estimated protein copy number/cell of the glucose transporters, GLUT1 and
GLUT3, for all IEL subsets ± 24 h IL-15/Rα stimulation (n= 4 biologically independent experiments). b Bar graph shows the glucose levels remaining in the
medium of IEL cultures in the presence of either 10 ng/mL or 100 ng/mL IL-15/Rα for 72 h. Levels of glucose remaining in the medium were assessed by
bioluminescence assay, data are presented as relative light units (RLU). The dotted line depicts the signal from the control wells containing only medium
but no cells (n= 3 biologically independent experiments). c Estimated protein copy number/cell of the lactate transporters MCT1 and MCT3 and the
glycolytic enzyme hexokinase 2 (HK2). Data is shown for all IEL subsets ± 24 h IL-15/Rα stimulation (n= 4 biologically independent samples), exact p-
values can be found in Supplementary Data 3. d Lactate output from IEL cultured as in b (n= 3 biologically independent experiments). e Mitochondrial
respiration measurements in IEL cultured in 10 ng/mL100 ng/mL IL-15/Rα for 44 h (n= 3 biologically independent samples). Oxygen consumption is
expressed as pmol O2 • s−1 •million cells−1. Respiratory rates were measured in cells (BASAL), then the cells were permeabilized with 10 μg/mL Digitonin,
and mitochondrial respiratory rates measured after the subsequent addition of glutamate and malate (GML), ADP to stimulate respiration (GMP) along
with succinate to stimulate complex II (GMSP), uncoupler (CCCP) to measure maximal electron transport (GMSE), rotenone to block complex I (SE) and
Antimycin A to inhibit complex III. The residual oxygen consumption after rotenone and Antimycin A treatment was subtracted from all values shown here.
OXPHOS oxidative phosphorylation, ETC electron transfer system capacity. All error bars are mean ± s.e.m. For all proteomic data (a, c), statistical
significance was derived from two-tailed empirical Bayes moderated t-statistics performed in limma on total proteome, see Supplementary Data 3. All
other data (b, d, e) were analysed by two-way ANOVA with Sidak’s multiple comparisons test.
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of the TCR via anti-CD3. To investigate whether IEL require
Granzymes to kill, we performed cytotoxic killing assays using
Gzma−/−Gzmb−/− (GzmA/B dKO) mice. In contrast to WT,
GzmA/B dKO IEL treated with IL-15 failed to kill any of the
target cells and even had the opposite effect of increasing K562
cell viability. This effect was only poorly reversed by TCR
stimulation (Fig. 5d). These results suggest that GzmA/B are
crucial for IEL killing and that other cytotoxicity-inducing
molecules such as TRAIL and FasL do not replace granzymes














































































































































































































Fig. 5 IL-15 potentiates IEL cytotoxicity. a Estimated protein copy number/cell of cytotoxic molecules granzyme A (GzmA), granzyme B (GzmB), Perforin,
Munc13-4, STXBP2 and RAB27A. Data are shown for all IEL subsets ± 24 h IL-15/Rα stimulation (n= 4 biologically independent samples), statistical
significance was derived from two-tailed empirical Bayes moderated t-statistics performed in limma on total proteome, see Supplementary Data 3. b Flow
cytometric analyses of intracellular GzmA and GzmB in freshly isolated IEL compared to those cultured with 100 ng/mL IL-15/Rα for 24 h. Data are
presented as mean fluorescence intensity (MFI) and percentage positive cells for GzmB (gating strategy shown in Supplementary Fig. 6c), (n= 3
biologically independent experiments), analysed by two-way ANOVA with Sidak’s multiple comparisons test. c Luciferase-transduced K562 cells were co-
cultured for 24 h with freshly isolated IEL at an effector to target (E:T) ratio of 40:1. Cells were treated with either 10 ng/mL or 100 ng/mL IL-15/Rα
(±aCD3). d Luciferase-transduced K562 cells were co-cultured for 24 h with freshly isolated IEL or WT and GzmA/B dKO IEL that had been pre-treated
with 100 ng/mL IL-15/Rα (±aCD3) for 72 h, at an E:T ratio of 40:1. c, d Bar graphs represent the percentage of specific lysis for each condition, (n= 3
biologically independent experiments) data were analysed by one-way ANOVA, with Sidak’s multiple comparisons test. All error bars are mean ± s.e.m.
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driven cytotoxicity is mediated by granzymes, and that upregula-
tion of GzmB is unlikely to be the main mechanism involved.
IL-15 upregulates multiple activating and inhibitory receptors
on IEL. Previous studies have reported that IEL derived from
patients with CeD had elevated expression of activating NK cell
receptors NKG2D and CD949,11. We only observed a modest
increase of NKG2D exclusively in TCRαβCD8αα IEL, and CD94
exclusively in TCRγδCD8αα IEL (Fig. 6a, b). Using flow cyto-
metry, we confirmed that NKG2D was not expressed by IEL in
the resting state, but expression was upregulated in a small per-
centage (~2–8%) of TCRαβCD8αα IEL specifically following IL-
15/Rα treatment, and this did not increase drastically even after
72 h of culture (Fig. 6a). Similarly, CD94 was expressed mainly by
~5–15% of TCRαβCD8αα and TCRγδCD8αα IEL (Fig. 6b). Thus,
CD94 and NKG2D are unlikely to be direct targets of IL-15 in the
mouse small intestine.
IEL are known to express a range of other surface receptors
and the proteomic data revealed that many of these were
upregulated following IL-15/Rα stimulation in all IEL subsets
(Fig. 6c). A number of these receptors have the potential to
impact upon the activation and cytotoxic effector function of IEL
such as adhesion molecules (e.g. ICAM2, Integrin α4, L1CAM)
and various activating receptors, such as the junctional adhesion
molecule-like (JAML) receptor and CD100 (Semaphorin 4D),
both co-stimulatory receptors for TCRγδ T cells in the skin32–35,
and CD226 (DNAM-1), a cytotoxic activator of NK cells36
(Fig. 6d). On the other hand, we also noted that IL-15/Rα led
to the upregulation of various inhibitory receptors such as LAG3,
LILRB4 and CD96 (Fig. 6e). Thus, the potential of IL-15 to
activate IEL in vivo may be driven through increased adhesion to
IEC, and the complex balance of both activating and inhibitory
signals received through multiple receptors besides NKG2D
and CD94.
Identification of PIM1/2 kinases as regulators of IEL responses
to elevated IL-15 signals. Among proteins that were not
expressed in IEL ex vivo but upregulated substantially by strong
IL-15/Rα signals were the PIM kinases, PIM1 and PIM2 (Fig. 7a).
PIM proteins are serine/threonine kinases transcriptionally
regulated downstream of JAK/STAT signalling37. Using immu-
noblotting, we confirmed a clear induction of the two isoforms of
PIM1, and all three isoforms of PIM2 in IEL stimulated with IL-
15/Rα (Fig. 7b). Despite no detectable protein expression of PIM1
and PIM2 in ex vivo IEL, mRNA for both Pim1 and Pim2 were
detected in ex vivo IEL, and this was significantly upregulated
upon IL-15 stimulation (Supplementary Fig. 2c). While PIMs
have been shown to play a key role in proliferation, cell survival
and protein synthesis, their functions are highly cell type and
context-specific and a role in IEL has not yet been defined38. To
assess the contributions of PIM kinases to IL-15-stimulated IEL,
we isolated IEL from Pim1−/−/Pim2−/Y (PIM1/2 dKO) mice.
Lack of PIM1 and PIM2 expression was confirmed via immu-
noblotting in splenic CD8 T cells, which had normal pSTAT5
levels (Supplementary Fig. 2a, b). PIM-deficient mice are healthy
and have normal complement of lymphocytes in the spleen
(Supplementary Fig. 2d). As IL-15 is crucial for IEL survival
in vivo, it was possible that IL-15 might require PIM kinases for
survival. However, IEL numbers and composition were normal in
PIM1/2 dKO mice (Fig. 7c), and their survival was unperturbed
in response to low levels of IL-15 (Fig. 7d). Conversely, responses
to high levels of IL-15/Rα were severely impaired in PIM1/2 dKO
mice. WT IEL numbers increased over 96 h in response to 100 ng/
mL IL-15/Rα in vitro, whereas PIM1/2 dKO IEL failed to increase
in numbers comparatively (Fig. 7e), and cell division was
completely abolished in PIM1/2 dKO mice (Fig. 7f). Strikingly,
defective proliferation in PIM1/2 dKO lymphocytes appears
specific to IEL, as activated splenic T cells proliferated normally in
the presence of IL-2 (Supplementary Fig. 2e, f), another γc family
cytokine that also induces the PIM kinases39. We also assessed the
individual contributions of PIM1 and PIM2 and found that loss
of either PIM1 or PIM2 on their own did not have as strong an
effect on IEL proliferation (Supplementary Fig. 3a, b).
PIM kinases can also regulate protein synthesis in cancer
cells40. Hence, we assessed cell growth in PIM-deficient IEL, and
found that dKO IEL failed to grow in size and granularity as
compared to WT IEL exposed to high levels of IL-15 (Fig. 7g).
PIM regulation of growth was also specific to IEL as splenic CD8
T cell growth was unperturbed in the absence of PIMs
(Supplementary Fig. 2g). As previously shown, IEL express high
levels of GzmA and GzmB in the resting state, however, PIM
dKO IEL had significantly lower expression of GzmB (Fig. 7h)
and failed to upregulate GzmB further in response to IL-15/Rα
(Fig. 7i). GzmA levels were normal in PIM dKO IEL
(Supplementary Fig. 2h). The mammalian target of Rapamycin
(mTOR) regulates protein synthesis and growth in T cells, and
our data revealed mTORC1 activity in IL-15-stimulated IEL, as
measured by phosphorylation of the mTOR target ribosomal
protein S6 (RPS6), despite only a modest increase in RPS6 copy
numbers (Supplementary Fig. 4a, b). Treatment of IEL with
Rapamycin, an mTORC1 inhibitor, blocked IEL growth and
proliferation downstream of IL-15/Rα, and marginally blocked
GzmB upregulation (Supplementary Fig. 4c, d, e). Importantly, in
the absence of PIM kinases, mTORC1 was not active, as
measured by phosphorylation of S6 (Supplementary Fig. 4f).
These data indicate that the PIM kinases may regulate growth and
protein synthesis in IEL by regulating mTOR function.
Given the observed functions of PIM kinases downstream of
IL-15/Rα signalling in mouse IEL, we next asked whether human
IEL also upregulate PIM kinase expression in the context of IL-15
and/or CeD. Analyses of recently published RNA-Seq datasets on
human TCRαβCD8αβ IEL cell lines, and on ex vivo IEL
stimulated with soluble IL-15 indicated that human IEL
upregulated Pim1 and Pim2 mRNA upon IL-15 stimulation
(ref. 15 and Supplementary Fig. 5a). Published microarray
analyses on T cell clones derived from human IEL and peripheral
blood lymphocytes (PBL) from CeD patients revealed that both
Pim1 and Pim2mRNA are higher in IEL compared to PBL (ref. 12
and Supplementary Fig. 5b). To test whether increased mRNA
expression of Pim1 and Pim2 corresponds to evidence of
increased protein expression, we examined the immunohisto-
chemical expression of PIM1 kinase by comparing duodenal
biopsies in CeD versus normal controls. PIM1 staining was more
intense in IEL in CeD biopsies compared to the weak staining in
normal controls, a feature broadly present across the biopsies
compared (Fig. 7j). Together these data indicate that upregulation
of PIM kinases by IL-15 may be a conserved pathway for
regulating IL-15 responses in IEL.
Discussion
IEL are one of the least understood T lymphocyte subsets, with
limited insights into their biology and regulation. Using high-
resolution mass spectrometry, we reveal the IL-15-regulated
proteomes of three distinct IEL subsets; TCRαβCD8αβ,
TCRαβCD8αα and TCRγδCD8αα. By focussing on IL-15, a key
cytokine that activates IEL function, we characterise the pathways
and modules regulating IEL activation, proliferation and pro-
teome remodelling. We observed that the major effect of IL-15
complexes on IEL is to trigger their proliferation, not only by
inducing the cell cycle machinery, but also by activating all the
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Fig. 6 Activating and inhibitory receptor expression in response to IL-15/Rα stimulation. Estimated protein copy number/cell of a NKG2D and b CD94,
with corresponding flow cytometric analyses on either ex vivo vs 24 h IL-15-stimulated IEL (top left panels) or IEL that had been cultured in 2 ng/mL or 100
ng/mL IL-15/Rα for 72 h (bottom left panels). Flow cytometry data (n= 3 biologically independent experiments) are presented as percentage positive cells
following gating on IEL subsets (gating strategy as in Supplementary Fig. 1a). c Row normalized heatmap showing the expression profile of a manually
curated list of surface receptors identified in the proteomics across IEL subsets. Grey squares indicate undetectable expression. d, e IEL were cultured in 2
ng/mL or 100 ng/mL IL-15/Rα for 72 h and assessed for their expression of various surface receptors identified in the heatmap. Flow cytometric data are
shown as mean fluorescence intensity (MFI) for d activating receptors; JAML, CD100 and DNAM-1, and e inhibitory receptors; LILRB4, LAG3 and CD96.
Gating strategy as in Supplementary Fig. 1a (n= 3 biologically independent experiments, except for LILRB4 (n= 2 biologically independent experiments).
All error bars are mean ± s.e.m. For all proteomic data (top right panels a, b), statistical significance was derived from two-tailed empirical Bayes
moderated t-statistics performed in limma on total proteome, see Supplementary Data 3. All flow cytometry data (a, b, d, e) were analysed by two-way
ANOVA with Sidak’s multiple comparisons test.
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accompanying changes required, such as protein and nucleotide
synthesis, ribosome biogenesis, and targeted bioenergetic activa-
tion to fuel these changes, largely regulated by the PIM kinases.
IL-15 also induced cell surface proteins involved in epithelial
interactions, particularly cell adhesion molecules and cytotoxic
activators that regulate IEL function.
With no known endogenous antigenic stimuli, it has been difficult
to define the mechanisms necessary for IEL activation. IL-15 can
induce cytolytic effector function in human IEL in the context of
certain target cells7,41. It has previously been suggested that IL-15
triggers IEL cytotoxic activity by upregulating expression of GzmB,
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IEL12,42. However, we find only modest upregulation of NKG2D, on
a very small proportion of IEL. We also reveal that IEL express the
complete cytotoxic machinery, including GzmB, prior to IL-15 acti-
vation, so it is not clear how further IL-15-induced upregulation of
GzmB would activate IEL cytotoxicity. Undeniably, there are differ-
ences between human and mouse IEL. For example, NKG2D is not
constitutively expressed on IEL in mice, whereas it is on resting
human IEL11,14. Further, TCRαβCD8αβ induced IEL, rather than
natural IEL subsets, are the most predominantly expressed subset in
humans2 and the primary mediators of tissue destruction in CeD.
Despite these apparent differences, we find that IL-15 also increased
the cytolytic activity of mouse IEL dramatically, particularly when
combined with TCR stimulation. Moreover, mice overexpressing IL-
15 in the intestine display signs of villous atrophy, suggesting that IEL
can be activated to kill IEC in the presence of elevated levels of IL-
1543. Yet even in these settings, less than 10% of IEL were shown to
express NKG2D42–44. Therefore, we suggest that other mechanisms
must be contributing to IL-15 driven cytotoxicity of IEL.
Our data revealed upregulation of various activating receptors,
such as JAML and CD100 in response to 24 h IL-15 stimulation.
JAML was recently reported to act as a co-stimulatory receptor
for epidermal TCRγδ T cells, increasing proliferation and cyto-
kine production upon interaction with its ligand CAR on
keratinocytes33. Similarly, CD100 was shown to specifically reg-
ulate intestinal TCRγδ IEL activation in the context of colitis and
epidermal wound repair34,35. CD226 is also expressed on human
IEL, and its activation on NK cells and CD8 T cells has been
described to trigger cytotoxicity, proliferation, and cytokine
production36,45. In our proteomic data, these receptors were not
only expressed by TCRγδ IEL but shared by all IEL subsets and
IL-15 stimulation commonly increased their expression, high-
lighting potential mechanisms for IL-15-induced activation of
IEL. Another possible explanation for the increased cytotoxic
activity of IL-15 stimulated IEL is that IL-15 lowers the signalling
threshold required for TCR or other co-receptor activation.
One fundamental insight from our proteomic data was the IL-
15-induced upregulation of PIM1 and PIM2. Despite the low-
level IL-15 signalling that occurs in vivo, we did not detect PIM1
or PIM2 expression in ex vivo IEL, suggesting that there is a
threshold of IL-15 signalling required to trigger the expression of
these kinases. Using PIM1/2-deficient mice we have shown that
IEL depend on both PIM kinases for their proliferative expansion
and growth in response to IL-15 in vitro. Interestingly, PIM1/2-
deficient IEL appeared phenotypically normal in unchallenged
mice, except for a reduction in GzmB expression. It is also
noteworthy that in the absence of PIM kinases, IL-15 could not
induce upregulation of GzmB. These data suggest that the PIM
kinases also control the cytotoxic activation of IEL.
Intraepithelial lymphocytosis and villous atrophy, both hall-
marks of CeD, are thought to be driven by IL-15. Currently the
only treatment available for CeD patients is a life-long gluten-free
diet. However, issues due to cost, non-compliance with the diet,
and gluten contamination cause symptoms in up to 30–50% of
CeD patients. Additionally, in a small percentage of CeD patients,
even being gluten-free does not reduce inflammation, leading to
RCeD46. Hence, there is an urgent need for treatments for CeD,
RCeD and associated lymphomas. Currently, IL-15 blocking
antibodies are being investigated as a treatment strategy47, with
limited success48,49, thus identifying new targets for small mole-
cule inhibitors would be beneficial. Our finding that PIM1 is
overexpressed in CeD biopsies suggest that PIM kinase inhibitors
may be effective for treatment of CeD and RCeD. PIM kinase
inhibitors are currently in clinical trials for the treatment of
certain types of haematological malignancies and solid
cancers50,51, thus there is clear potential for these drugs to also be
used for the treatment of CeD and its complications.
This study provides a comprehensive proteomic analyses of the
effects of strong IL-15 stimulation on IEL. The effects of IL-15 on
IEL receptor expression and biosynthetic pathways, among oth-
ers, are unstudied pathways that warrant further investigation. In
particular, the identification of the PIM kinases as key regulators
of IEL biology is a pivotal finding of this study. Further research
will reveal the mechanisms by which PIM kinases orchestrate IEL
biology and immune responses, and whether this a feature spe-
cific to IEL. The proteomics data and insights obtained in this
study will serve as an important resource, not only for the study
of IEL in CeD, but also in the context of infection, inflammatory
bowel diseases and cancer, where IL-15 is overexpressed.
Methods
Mice. All mice were bred and maintained with approval by the University of
Dundee ethical review committee, under a UK Home Office project license
Fig. 7 PIM kinases regulate IEL responses to strong IL-15/Rα stimulation. a Estimated copy number/cell of PIM1 and PIM2 kinases in IEL ± 24 h IL-15/Rα
stimulation (n= 4 biologically independent experiments), statistical significance was derived from two-tailed empirical Bayes moderated t-statistics
performed in limma on total proteome, see Supplementary Data 3. b Immunoblot data (representative of n= 3 biologically independent experiments)
showing PIM1 (right) and PIM2 (left) expression in ex vivo IEL or 24 h IL-15-stimulated IEL. Antibodies against GAPDH were used as a loading control. c Bar
graphs show the absolute cell counts (left; n= 6 biologically independent experiments) and subset composition (right; n= 3 biologically independent
experiments) of IEL isolated from WT (red) and PIM1−/−/PIM2−/Y (PIM1/2 dKO) (grey) mice (gating strategy shown in Supplementary Fig. 6c). d The
percentage of live IEL from either WT or PIM1/2 dKO mice that were cultured in 2 ng/mL IL-15/Rα for 96 h (n= 3 biologically independent experiments).
Percentages were calculated from the number of live cells following IL-15/Rα treatment divided by the number of cells seeded for culture (1 million/mL)
every 24 h. e Line graph shows the cell numbers of IEL from either WT or PIM1/2 dKO mice that were cultured in 100 ng/mL IL-15/Rα for 96 h (n= 3
biologically independent experiments). f IEL were isolated fromWT and PIM1/2 dKO mice and stained with CellTrace CFSE prior to stimulation with 100 ng/
mL IL-15/Rα for 4 days. Every 24 h cells were stained for subsets and CFSE expression was analysed by flow cytometry (gating strategy as in Supplementary
Fig. 1a). The discrete peaks in the histograms represent successive generations of live, DAPI-negative IEL (n= 3 biologically independent experiments). g Dot
plots (representative of n= 3 biologically independent experiments) show the forward scatter (FSC) vs side scatter (SSC) of live IEL ex vivo as compared to
IEL cultured in 100 ng/mL IL-15/Rα for 72 h from both WT (top) and PIM1/2 dKO (bottom) mice. IEL that were h derived ex vivo and i cultured in 100 ng/
mL IL-15/Rα from both WT and PIM1/2 dKO mice were stained for intracellular GzmB expression (gating strategy as in Supplementary Fig. 1a), presented as
mean fluorescence intensity (MFI) normalized to h WT controls or i cells cultured in 2 ng/mL IL-15/Rα (n= 3 biologically independent experiments).
j Representative images of normal duodenal (n= 8) or duodenal biopsies with histological features of coeliac disease (n= 8) stained with anti-PIM1 and
anti-CD3 antibodies (scale bar= 100 µm). I and II (top panels) show a biopsy of normal control duodenum and III and IV (bottom panels) show features
consistent with coeliac disease. Boxplot demonstrates semi-quantitative assessment of PIM1 immunohistochemical staining intensity from biopsies,
whiskers are minima to maxima with all points shown. All error bars are mean ± s.e.m. For (c, right panel) a two-tailed unpaired t-test with Sidak’s multiple
comparisons test and j two-tailed Mann–Whitney test was used to derive statistical significance. (c, left panel), d, h, i were analysed by two-way ANOVA
with Sidak’s multiple comparisons test.
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(PD4D8EFEF) in compliance with U.K. Home Office Animals (Scientific Proce-
dures) Act 1986 guidelines. C57BL/6 J male mice were purchased from Charles
Rivers and acclimatised for a minimum of 10 days prior to use in experiments at
50–60 days old. Pim1−/− /Pim2−/Y (PIM1/2 dKO), Pim1−/− (PIM1 sKO) and
Pim2−/Y (PIM2 sKO) mice38 on C57BL/6 J background were obtained from D.
Cantrell, University of Dundee, Scotland with permission from A. Berns, Neth-
erlands Cancer Institute (NKI-AVL), Amsterdam. PIM1/2 dKO experiments were
both male and female, aged 70–300 days old with age and sex-matched non-
littermate wild-type controls. PIM1 sKO proliferation experiments were both
male and female mice aged 70–300 days old with age and sex-matched littermate
wild-type controls. PIM2 sKO proliferation experiments were male mice aged
70–80 days old with age and sex-matched littermate wild-type controls. Gzma−/−/
Gzmb−/− (GzmA/B dKO) mice on C57BL/6 J background were obtained from J.
Pardo, University of Zaragoza, Spain52. GzmA/B dKO killing assay were both male
and female mice aged 80–110 days old, with co-housed age and sex-matched
C57BL/6 J wild-type controls.
Mice were maintained in a standard barrier facility on a 12 h light/dark cycle at
21 °C, 45–65% relative humidity. Mice were tested negative for all pathogens on the
current FELASA list. Mice were maintained in individually ventilated cages with
corn cob or Eco Pure chips 6 and sizzler-nest material and fed an R&M3 diet
(Special Diet Services, UK) and filtered water ad libitum. Cages were changed at
least every two weeks.
Isolation of IEL from the intestinal epithelium. IEL were isolated as described53.
Briefly, small intestines were dissected from proximal duodenum to terminal ileum
and using a gavage needle, flushed with 20 mL cold PBS to remove luminal con-
tents. Intestines were cut longitudinally and then transversely into small 5–10 mm
pieces. The pieces were placed into 25 mL complete RPMI media (RPMI+ 10%
FBS, 1% Pen/Strep & L-glutamine) with 1 mM DL-Dithiothreitol (DTT) and
incubated on a shaker for 40 min at RT. After centrifugation and vortexing in
complete RPMI media the cells were passed through a 100 µm strainer and isolated
cells were centrifuged in a 36%/67% Percoll/PBS density gradient at 700 × g for
30 min with no brake. IEL appear as diffuse layer at the interface between the two
Percoll concentrations.
Sample preparation for mass spectrometry. For proteomics experiments, four
biological replicates were generated and IEL were isolated from eight mice per
biological replicate (male, C57BL/6, aged 10-12 weeks). IEL were isolated from the
small intestine as previously described. For further enrichment of the CD8α+ IEL
population, following Percoll density gradient centrifugation, an EasySep Release
PE positive selection kit (STEMCELL Technologies, #17656) was used with a PE-
conjugated anti-mouse CD8α antibody (BioLegend, #100708) as per the manu-
facturer’s instructions. Cells were stained with PerCP eFluor 710 (TCRγδ), APC
(TCRβ), PE (CD8α), FITC (CD8β) and PE-Cy7 (CD4) for isolation of pure
populations of TCRγδCD8αα, TCRαβCD8αα and TCRαβCD8αβ IEL using fluor-
escent activated cell sorting (FACS) (Supplementary Fig. 1A, full list of antibodies
provided in Supplementary Data 5). We purified ~10million TCRγδCD8αα, ~5
million TCRαβCD8αα and ~5 million TCRαβCD8αβ per biological replicate. Two
million cells from each purified cell population were pelleted and snap frozen in
liquid N2 and the remaining cells treated with 100 ng/mL IL-15/Rα for 24hrs as
described below then similarly pelleted and snap frozen.
IEL cell pellets (both IL-15-treated and untreated) were lysed in 200 µL lysis
buffer (4% SDS, 10 mM TCEP, 50 mM TEAB (pH 8.5)). Lysates were boiled and
sonicated (15 cycles of 30 s on/30 s off) and protein concentrations determined by
EZQ Protein Quantitation Kit (Invitrogen, #R33200). Lysates were then alkylated
with iodoacetamide (IAA) for 1 h at room temperature in the dark. For protein
clean-up, 200 µg SP3 beads54 were added to lysates before elution in digest buffer
(0.1% SDS, 50 mM TEAB (pH 8.5), 1 mM CaCl2) and digested with LysC and
Trypsin, each at a 1:100 (µg enzyme:protein) ratio. Peptide clean-up was performed
according to the SP3 protocol. Samples were resuspended in 2% DMSO and 5%
formic acid. For fractionation, off-line high pH (9.5) reverse phase chromatography
was used. Using an Ultimate 3000 HPLC (Thermo Scientific), peptides were
separated into 16 concatenated fractions, then manually pooled to 8 orthogonal
fractions, dried and eluted into 5% formic acid for analysis by LC-MS. Samples
were sent to MRC-PPU Mass Spectrometry facility, University of Dundee, where
each fraction was analysed by label-free quantification (LFQ) using an LTQ-
Orbitrap Velos Pro mass spectrometer running Xcalibur software (v.
2.1.0SP1.1160) (Thermo Scientific) with a 240-minute gradient per fraction.
Processing and statistical analysis of proteomics data. The MS raw data files
were processed with MaxQuant version 1.6.8.0 as described39, against mouse
reviewed proteome from Swissprot with isoforms, downloaded in Aug 2019.
Minimum peptide length was set to 6, and proteins were quantified on unique+
razor peptides with the following modifications included: Oxidation (M); Acetyl
(Protein N-term); Deamidation (NQ). The dataset was filtered to remove proteins
categorised as “contaminants”, “reverse” and “only identified by site” (a summary
detailing protein identification in each sample is provided in Supplementary
Data 4). Pearson’s correlation coefficients for each of the samples was calculated
using the associated protein intensities and subsequent heatmaps were plotted in
the ‘proteus’ package55 in RStudio. MaxQuant-derived data were converted into
estimated copy numbers per cell as described19. Protein (i) copy number (CN(i))
was calculated using the following formula: NA*5.5*MS-intensity(i)/ (total histone
MS intensities*MW(i), where MW is the protein molecular weight in Daltons, NA is
Avogadro’s Constant, and 5.5 pg is the estimated weight of 2n DNA content in
mouse cells. The protein content was calculated using the following formula:
5.5*total MS intensities/total histone MS intensities= protein mass (pg/cell). For
differential expression analyses, p-values and fold changes were calculated on log2-
normalized copy numbers using the limma package in R56,57. All comparisons were
made using the default conditions for the package. P-value adjustment was per-
formed using the Benjamini-Hochberg (BH) method, and associated q values were
calculated using the Bioconductor package ‘qvalue’, a list of which can be found in
Supplementary Data 3. Elements with p-values < 0.05 were considered significant.
Fold-change thresholds were determined using 1 standard deviation of the mean
log2[fold change] in each IEL subset as a guide. Complete analysed data are in
Supplementary Data 3. Following DE analysis, only proteins with >2 peptides
quantified were retained to reduce the impact of false positive identifications. For
functional annotation analysis of proteins identified, the Database for Annotation,
Visualization and Integrated Discovery (DAVID) Bioinformatics resources 6.858,59
was used (https://david.ncifcrf.gov/tools.jsp). Heatmaps were generated using the
Morpheus tool (https://software.broadinstitute.org/morpheus) from the Broad
Institute.
Cell culture of IEL and cytotoxicity assay. Isolated IEL were further enriched
using an EasySep Mouse CD8α positive selection kit II (STEMCELL technologies,
#18953) as per the manufacturer’s instructions. IEL positively enriched for CD8α
expression were resuspended in culture medium (RPMI+ 10% FBS+ 1% Pen/
Strep, L-glutamine, sodium pyruvate, non-essential amino acids, 2.5% HEPES and
0.1 mM β-mercaptoethanol) with various concentrations of Mouse IL-15/IL-15R
Complex Recombinant Protein (referred to as IL-15/Rα) (ThermoFisher, #14-
8152-80). These cells were seeded in a round-bottom 96-well plate at 1 million
cells/mL (2 × 105 cells per well) and incubated at 37 °C, 10% CO2. For rapamycin
treatment, 20 nM of InSolution Rapamycin (Merck, #553211) was added to cells in
the presence of 100 ng/mL IL-15/Rα and cultured for specified amount of time in
figures. For analysis of proliferation, CellTrace CFSE Cell Proliferation Kit (Invi-
trogen, #C34554) was used; briefly, cells were treated with 5 μM CFSE at 37 °C for
10 min before quenching in ice cold PBS+ 15% FCS and put into culture as
described above. For the bioluminescence-based cytotoxicity assay, luciferase-
expressing K562 cells (provided by Dr. S. Minguet, Freiburg) were plated at a
concentration of 5 × 103 cells per well in a 96-well flat bottom plate in triplicates.
75 μg/mL D-firefly luciferin potassium salt (Biosynth, #L-8220) was added to the
K562 cells and bioluminescence was measured using a PHERAstar plate reader to
establish the bioluminescence baseline. For a maximal cell death (positive control),
triton X-100 was added to K562 cells at a final concentration of 1%. For sponta-
neous death (negative control), culture medium was added to K562 cells. For the
test, WT or GzmA/B dKO IEL that had been cultured for 72hrs in 100 ng/mL IL-
15/Rα were added to K562 cells at a 40:1 effector-to-target (E:T) ratio and incu-
bated for 24hrs at 37 °C, 10% CO2. Bioluminescence was measured as relative light
units (RLU). Percentage specific lysis was calculated with the following formula: %
specific lysis= 100 × (average spontaneous death RLU− test RLU)/(average
spontaneous death RLU− average maximal death RLU).
Cell culture and treatments for splenocytes and lymph nodes. Single-cell
suspensions from WT and PIM1/2 dKO spleens were activated with purified anti-
CD3+ anti-CD28 [both 0.5 µg/mL, clones 2C11 and 37.51, respectively,
(eBioscience, #100302/BioLegend, #102116)] in the presence of recombinant
human IL-2 [20 ng/mL (Proleukin, Novartis)]. After 48 h cells were washed out of
activation media, then split daily into fresh media and IL-2 (20 ng/mL) to a density
of 0.3 million cells/mL. CD8 T cell numbers of WT and PIM1/2 dKO T cells were
counted on a FACSVerse daily from day 2 of the culture onwards. Lymph node
single-cell suspensions from WT and PIM1/2 dKO were labelled with 5 µM Cell-
Trace Violet Cell Proliferation Kit (CTV) (Invitrogen, #C34557) for 20 min at 37 °
C, washed then activated with anti-CD3+ anti-CD28 [both 0.5 µg/mL clones 2C11
and 37.51, respectively, (eBioscience/Thermo Fisher Scientific)] at 100,000 cells per
well in 96-well flat-bottomed plate in 200 µL total volume for 4 days. Cells were
stained with Propidium Iodide (PI) (Sigma, #P4170) at a final concentration of 0.2
µg/mL before surface staining with CD4 and CD8 as described in ‘flow cytometry’
section. Cell proliferation was assessed daily by flow cytometry.
Measurement of extracellular metabolites in cell culture. IEL were isolated and
enriched for CD8α as previously described before plating at 200,000 cells/well in a
round-bottom 96-well plate in 200 µL medium (glucose-free RPMI to which 2 mM
glucose, 2 mM L-glutamine 10% dialysed FBS, 1% Pen/Strep, sodium pyruvate,
non-essential amino acids, 2.5% HEPES and 0.1 mM β-mercaptoethanol were
added). Cells were cultured at 37 °C, 10% CO2 and every 24 h 10 µL of medium was
removed, diluted in 190 µL of PBS and further diluted 2.5x for glucose measure-
ments. Samples were frozen and stored at −20 °C. At the end of the experiment,
samples were thawed and 50 µL aliquots transferred to a 96-well assay plate
(Corning,#3903). Each sample was plated in duplicate for each metabolite. The
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metabolites were then detected using the Lactate-Glo and Glucose-Glo assays
(Promega, #J5021, #J6021) as per manufacturer’s instructions. Luminescence was
recorded using a PHERAstar plate reader and measured as relative light
units (RLU).
Flow cytometry. Cells were plated at 2 × 105 cells per well to a 96-well dish for
staining. FC block (BioLegend, #147605) was added to each well for 5 min before
cells were incubated with monoclonal antibodies (mAb) against cell surface mar-
kers for 15 min at 4 °C. Cells were stained with the following antibodies specific for
murine: CD45 [clone 30.F11 (BioLegend)], TCRβ [clone H57-597 (BioLegend)],
TCRγδ [clone GL3 (BioLegend or eBioscience)], CD4 [clone RM4-5 (BioLegend)],
CD8α [clone 53-6.7 (BioLegend)], CD8β [clone H35-17.2 (eBioscience)], CD122
(IL-15Rβ) [clone TM-b1 (eBioscience)], NKG2D [clone CX5 (BioLegend)], CD94
[clone 18d3 (BioLegend)], JAML [clone HL4E10 (BioLegend)], CD100 [clone
BMA-12 (BioLegend)], CD223 (LAG3) [clone eBioC9B7W (eBioscience)] and
CD85k (LILRB4) [clone H1.1 (BioLegend)], CD226 (DNAM-1) [clone 10E5
(eBioscience)], CD69 [clone H1.2F3 (eBioscience)], CD96 [clone 3.3 (BioLegend)],
CD71 [clone RI7217 (BioLegend)], CD98 [clone RL388 (BioLegend)]. DAPI
(Invitrogen, #D1306) was used as cell viability dye for live cells. Fixed cells were
treated with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Invitrogen, #L34962)
for dead cell discrimination. For fixation before intracellular staining, cells were
treated with 2% PFA at 37 °C for 10 min. For intracellular staining, cells were
washed in 1X permeabilization buffer (eBioscience, #00-8333-56) before 1 h
incubation at room temperature with mAbs specific for mouse: GzmB [clone GB12
(eBioscience)] or GzmA [clone GzA-3G8.5 (eBioscience)]. For detection of
phospho-STAT5 and phospho-S6 ribosomal protein by flow cytometry, cells were
fixed with 2% PFA prior to any surface stains, permeabilised with 90% ice cold
methanol and incubated with Rabbit monoclonal phospho-STAT5 (Tyr694) [clone
C11C5 (Cell Signaling Technology)] (1:200 dilution), or Rabbit monoclonal
Phospho-S6 Ribosomal Protein (Ser235/236) [clone D57.2.2E (Cell Signaling
Technology)](1:25 dilution) for 30 min at room temperature. Cells were then
incubated with an anti-rabbit DyLight 649-conjugated donkey secondary Ab [clone
Poly4064 (BioLegend)] for 30 minutes at room temperature (1:500 dilution). To
measure DNA synthesis or protein synthesis, cells were treated with 10 µM base-
click 5-Ethynyl-deoxyuridine (5-EdU) (Sigma, #BCK-FC647-50) for 2 h, or 20 µM
O-propargyl-puromycin (OPP) (JenaBioscience, #NU-931-05) for 15 minutes,
respectively. For OPP assays, a negative control was pre-treated with 0.1 mg/mL
Cycloheximide solution (Sigma, #C4859) for 30 min before adding OPP. Cells were
then harvested (~1 million cells per condition), fixed with 4% PFA and permea-
bilised with 0.5% triton X-100 before undergoing a copper catalysed click chemistry
reaction with Alexa 647-azide using the EdU Flow Cytometry Kit 647 (Sigma,
#BCK-FC647-50). Cells were then stained with surface markers as described above
and resuspended in FACS buffer (PBS+ 1% FBS (+15 µg/mL DAPI for cell cycle
analysis)) and analysed by flow cytometry to determine the degree of incorporation
of EdU or OPP. All data were acquired on a FACSVerse flow cytometer with
FACSuite software (version 1.0.5.3841, BD Biosciences) or a FACS LSR Fortessa
flow cytometer with DIVA software (version 8.0.1, BD Biosciences). Data were
analysed using FlowJo software (TreeStar). A list detailing all antibodies and
dilutions can be found in Supplementary Data 5.
Fluorescent cell barcoding (FCB). IEL were isolated and enriched for CD8+ as
described above. Cells were resuspended at a concentration of 1 million cells/mL
and 500 μL plated in a 24 flat bottom well plate. Cells were warmed at 37 °C for 30
min before stimulated with different concentrations of IL-15/Rα for 3 h at 37 °C.
After stimulation cells were directly fixed with 500 μL PFA 4% 10min at 37 °C
before permeabilisation with 90% ice cold methanol. During methanol permeabi-
lisation, each sample was stained with a mix of various concentrations of amine-
reactive fluorescent dyes for 40 min, on ice before quenching with PBS+ 0.5%BSA
(v:v). Pacific Blue Succinimidyl Ester (Invitrogen, #P10163) was used at a con-
centration of 0 μg/ml, 11.1 μg/ml or 100 μg/ml and DyLight800 NHS Ester
(Thermo Scientific, #46421) at a concentration of 0 μg/ml or 25 μg/ml. Barcoded
samples were then pooled and stained for intracellular pSTAT5 and surface
markers as described in the “flow cytometry” section. Data were acquired using
CytoFlex flow cytometer (Beckman Coulter) with CytExpert (v2.4.0.28) software
and analysed using FlowJo Software. Data were analysed using the “forward
deconvolution method”60. Briefly, samples were differentiated based on the
fluorescence intensities of each dye and then individual samples were analysed for
pSTAT5 expression.
High-resolution respirometry. Mitochondrial respiration was measured in
digitonin-permeabilised IELs that enables studying mitochondria in their archi-
tectural environment. CD8+ IEL were isolated and cultured as described above, in
10 ng/mL or 100 ng/mL IL-15/Rα for 44 h. The analysis was performed in a
thermostatic oxygraphic chamber at 37 °C with continuous stirring (Oxygraph-2k,
Oroboros instruments, Innsbruck, Austria). Approximately 1 million cells were
placed in Mir05 respiration medium (0.5 mM EGTA, 3 mM MgCl2, 60 mM lac-
tobionic acid, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM D-Sucrose
and 1 g/L of fatty acid free Bovine Serum Albumin [BSA]; pH= 7.1) in the oxy-
graphic chamber. Respiration protocol was adapted from the Substrate-uncoupler-
inhibitor titration protocol number 11 (SUIT-011)61. Briefly, after the determi-
nation of the BASAL oxygen consumption in absence of any substrate, cells were
permeabilized with digitonin (10 µg/106 cells). Substrates and inhibitors were then
added sequentially to determine respiratory rates. LEAK respiration was first
measured by adding glutamate (10 mM) and malate (2 mM) to the chamber
(GML). OXPHOS respiration was then determined by first adding 2.5 mM ADP
(GMP). The OXPHOS GMP state records electron flow from the type N-pathway
(NADH-generating substrates to complex I) to Q-junction that feeds electrons to
complexes III and IV. The maximal OXPHOS respiration rate GMSP was then
measured by adding 25 mM succinate, with both type N-pathway to Q and type S-
pathway (succinate, substrate of complex II) to Q being stimulated. Electron
transfer system capacity (ETC) was then assayed by adding incremental doses of
Carbonyl cyanide m-chlorophenyl hydrazine (CCCP) (0.05 µM steps, GMSE).
Complex I was blocked with 0.5 µM rotenone to determine the Succinate-pathway
control state (SE). Finally, residual oxygen consumption (ROX) was determined in
presence of 2.5 µM Antimycin A. ROX was subtracted from oxygen flux as a
baseline for all respiratory states. Respiratory rates were expressed as pmol O2 x s−1
x million cells−1.
Immunoblots. IEL were isolated and ex vivo samples were cultured with 10 ng/mL
IL-15/Rα for 2 h to allow for a basal level of PIM expression before harvesting 5
million cells and pelleting. Stimulated IEL were cultured as described above with
100 ng/mL IL-15/Rα for 24 h and then similarly refreshed in medium+ IL-15/Rα
for 2 h before harvesting. Cell pellets were lysed at between 50 and 60 million cells/
mL RIPA lysis buffer (50 mM Tris pH 7.4, 1% (v/v) NP-40, 0.5% (w/v) Na
deoxycholate, 0.1% (w/v) SDS, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 1 mM
TCEP, 5 mM Na-pyrophosphate, 10 mM Na-β-phosphoglycerate, 1 mM Na
Orthovanadate, cOmplete mini EDTA-free protease inhibitor tablet (Roche)) for
10 min on ice before centrifuging for 12 min at 4 °C. Protein concentrations were
determined for IEL lysates using the Coomassie (Bradford) Protein Assay Kit
(Thermo Scientific, # 23200) as directed. Lysates were boiled with NuPAGE LDS
sample buffer (4X) for 3 min at 100 °C. 20 μg of IEL lysate and ~140,000 CTL lysate
per well were separated using a 4% stacking/10% resolving SDS-PAGE gel at 120 V
for 100 min. Following separation, proteins were transferred to a PVDF membrane
for 90 min at 300 mA. Membranes were then blocked in 5% (w/v) milk (Marvel)/
PBS-Tween for 30 min at RT. Following blocking, membranes were washed and
incubated with primary monoclonal antibodies; anti-mouse PIM1 [clone 12H8
(Santa Cruz Biotechnology)] or anti-mouse PIM2 [clone 1D12 (Santa Cruz Bio-
technology)] both used at 1:100 in 5% (w/v) milk (Marvel)/PBS-Tween. Mono-
clonal anti-rabbit GAPDH [clone 14C10 (Cell Signalling Technology)] was used as
a loading control (1:1000 in 3% BSA/PBS-Tween). PanSTAT5, rabbit polyclonal
antibody [clone D2O6Y (Cell Signalling Technology)] and phospho-STAT5
(Tyr694), rabbit polyclonal antibody (Cell Signalling Technology, cat # 9351) both
used at 1:1000 in 3% BSA/PBS-Tween. For PIM1 and PIM2 antibody specificity
and selectivity (Supplementary Fig. 2a, b), gels were cut down to centre to blot for
phospho-STAT5 and PIMs from halves of the same membrane. Phospho-STAT5
membrane was then stripped with stripping buffer (200 mM glycine, 3.5 mM SDS,
1% Tween20) for 30 min, washed with PBS-Tween and reblotted for panSTAT5.
Membranes were washed out of primary and incubated with HRP-conjugated
secondary anti-mouse or anti-rabbit IgG (Cell Signalling Technology) at 1:5000 in
5% (w/v) milk (Marvel)/PBS-Tween, or 1:2000 in 5% BSA/PBS-Tween, respec-
tively. Membranes were exposed to Clarity Western ECL substrate or Clarity Max
Western ECL Substrate (BioRad, #1705061, #1705062) and signals were detected
using a ChemiDoc imaging system. A list detailing all antibodies and dilutions can
be found in Supplementary Data 5.
RNA extraction and qPCR. RNA was isolated using the PureLink RNA mini kit
(Invitrogen, # 12183018 A) as per manufacturer’s instructions, and complementary
DNA (cDNA) was generated using PrimeScript RT Reagent Kit with gDNA Eraser
(Takara, #RR047B). Real-time PCR was performed with the TB Green Premix Ex
Taq II (Takara, #RR820W) on a Biorad CFX384 Touch Real-Time PCR machine.
CD3ε was used as a reference gene. Data were analysed using the ΔCt method.
Primers were as follows: PIM1 5’- CAAACTGTCTCTTCAGAGTG -3’ (forward)
and 5’-GTTCCGGATTTCTTCAAAGG-3’ (reverse), PIM2 5’-ATGTTGACCAAG
CCTCTG-3’ (forward) and 5’-CGGGAGATTACTTTGATGG-3’ (reverse), CD3ε
5’- GAGAGCAGTCTGACAGATAGGAG-3’ (forward) and 5’GAGGCAGGAGA
GCAAGGTTC-3’ (reverse). Details of primers used are provided in Supplementary
Table 1.
Human tissue and immunohistochemistry. All human tissues were obtained with
written informed consent from donors under the governance of and with ethical
approval from the NHS Research Scotland Biorepository in Tayside. Formalin-
fixed paraffin embedded (FFPE) duodenal biopsies were obtained from patients
who had undergone oesophageal-gastro duodenoscopy in which the histological
features were subsequently in keeping with coeliac disease (n= 8) compared to
controls in which features were subsequently within normal limits (n= 8). Biopsies
selected for coeliac disease staining were restricted to those with intraepithelial
lymphocytosis, sub-total to total villous atrophy in the correct clinical (and ser-
ological) context for coeliac disease. Normal biopsies were those showing no
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histopathological abnormality. Sections from FFPE blocks (nominally 4 microns
thick) were cut onto superfrost plus slides (VWR International Ltd) and dried for
1 h at 60 °C. Antigen retrieval and de-paraffinization was performed using DAKO
EnVision FLEX Target Retrieval solution (high pH) buffer (Agilent Technologies,
#K8004) in a DAKO PT Link. Sections were blocked in Flex Peroxidase-Blocking
Reagent (Agilent Technologies, #SM801) and incubated overnight at 4 °C with
anti-PIM1 [clone 12H8 (Santa Cruz)] at a dilution of 1:25 and anti-CD3 (A0452,
Agilent) at a dilution of 1:100. Immunostaining using DAKO EnVision FLEX
system (Agilent Technologies) on a DAKO Autostainer Link48 was carried out
according to manufacturer’s protocol. DAKO substrate working solution was used
as a chromogenic agent for 2 × 5 min and sections were counterstained with
EnVision FLEX haematoxylin. Sections from mantle cell lymphoma known to stain
positively were included in each batch and negative controls were prepared by
replacing the primary antibody with DAKO antibody diluent. Slides were scanned
to produce whole slide images using the Leica Aperio CS2 system, and repre-
sentative image snapshots were then captured from the whole slide images at
equivalent to ×200 magnification. PIM1 stained coeliac and normal control slides
were randomised and the intensity of staining of PIM1 on the original slides were
scored by light microscopic assessment using a Nikon Eclipse Ni microscope. A
semi-quantitative scoring system from 0 to 3+ was used to evaluate the average
staining of intraepithelial lymphocytes across the whole of each biopsy. A list
detailing all antibodies and dilutions can be found in Supplementary Data 5.
Statistical analyses. Differential expression analyses from the proteomic data
were performed as outlined in the ‘Processing and statistical analysis of proteomics
data’ section. Further analysis on data derived from the proteomic data and all
validation experiments were analysed by two-way ANOVA, with Sidak’s multiple
comparison test unless otherwise stated in the figure legends. Statistical analyses
were carried out using GraphPad Prism v.8. For bar graphs, symbols on bars
represent independent biological replicates. Results are shown as mean ± s.e.m.
P-values <0.05 were considered to denote significance.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All analysed proteomics data generated during this study are provided in Supplementary
Data 3, with further analyses in Supplementary Data 1, 2 and 4. The mass spectrometry raw
data have been deposited in the ProteomeXchange Consortium via the PRIDE partner
repository62 with the dataset identifier PXD025891. Gene expression data from human
samples were obtained from publicly available Gene Expression Omnibus datasets
GSE120904 and GSE4592. A source data file is provided with this manuscript for all figures,
excluding data pertaining to; Fig. 1c which is provided in full in supplementary Data 3; data
pertaining to Fig. 1d and e are provided in supplementary Data 1; data pertaining to Fig. 1f
is provided in supplementary Data 2; and data pertaining to Supplementary Fig. 1c and d
are provided in supplementary Data 3. All other data supporting this study can be obtained
from the corresponding author upon request. Source data are provided with this paper.
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